Literature DB >> 28159735

The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications.

Hind Medyouf1.   

Abstract

Similar to their healthy counterpart, malignant hematopoietic stem cells in myeloid malignancies, such as myeloproliferative neoplasms, myelodysplastic syndromes, and acute myeloid leukemia, reside in a highly complex and dynamic cellular microenvironment in the bone marrow. This environment provides key regulatory signals for and tightly controls cardinal features of hematopoietic stem cells (HSCs), including self-renewal, quiescence, differentiation, and migration. These features are essential to maintaining cellular homeostasis and blood regeneration throughout life. A large number of studies have extensively addressed the composition of the bone marrow niche in mouse models, as well as the cellular and molecular communication modalities at play under both normal and pathogenic situations. Although instrumental to interrogating the complex composition of the HSC niche and dissecting the niche remodeling processes that appear to actively contribute to leukemogenesis, these models may not fully recapitulate the human system due to immunophenotypic, architectural, and functional inter-species variability. This review summarizes several aspects related to the human hematopoietic niche: (1) its anatomical structure, composition, and function in normal hematopoiesis; (2) its alteration and functional relevance in the context of chronic and acute myeloid malignancies; (3) age-related niche changes and their suspected impact on hematopoiesis; (4) ongoing efforts to develop new models to study niche-leukemic cell interaction in human myeloid malignancies; and finally, (5) how the knowledge gained into leukemic stem cell (LSC) niche dependencies might be exploited to devise novel therapeutic strategies that aim at disrupting essential niche-LSC interactions or improve the regenerative ability of the disease-associated hematopoietic niche.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2017        PMID: 28159735     DOI: 10.1182/blood-2016-11-696070

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.

Authors:  Catharina Wenk; Anne-Kathrin Garz; Sonja Grath; Christina Huberle; Denis Witham; Marie Weickert; Roberto Malinverni; Julia Niggemeyer; Michèle Kyncl; Judith Hecker; Charlotta Pagel; Christopher B Mulholland; Catharina Müller-Thomas; Heinrich Leonhardt; Florian Bassermann; Robert A J Oostendorp; Klaus H Metzeler; Marcus Buschbeck; Katharina S Götze
Journal:  Blood Adv       Date:  2018-12-11

Review 2.  Clinical consequences of clonal hematopoiesis of indeterminate potential.

Authors:  David P Steensma
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  The wolf of hypomethylating agent failure: what comes next?

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Haematologica       Date:  2019-08       Impact factor: 9.941

Review 4.  Making HSCs in vitro: don't forget the hemogenic endothelium.

Authors:  Bradley W Blaser; Leonard I Zon
Journal:  Blood       Date:  2018-08-08       Impact factor: 22.113

Review 5.  Genetics of MDS.

Authors:  Seishi Ogawa
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

6.  Cancer-associated fibroblasts promote colorectal cancer progression by secreting CLEC3B.

Authors:  Hui-Fang Zhu; Xu-Hui Zhang; Chuan-Sha Gu; Yan Zhong; Ting Long; Yi-Dan Ma; Zhi-Yan Hu; Zu-Guo Li; Xiao-Yan Wang
Journal:  Cancer Biol Ther       Date:  2019-03-20       Impact factor: 4.742

Review 7.  The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS).

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 8.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies.

Authors:  Robert L Bowman; Lambert Busque; Ross L Levine
Journal:  Cell Stem Cell       Date:  2018-02-01       Impact factor: 24.633

9.  EBF1-deficient bone marrow stroma elicits persistent changes in HSC potential.

Authors:  Marta Derecka; Josip Stefan Herman; Pierre Cauchy; Senthilkumar Ramamoorthy; Ekaterina Lupar; Dominic Grün; Rudolf Grosschedl
Journal:  Nat Immunol       Date:  2020-02-17       Impact factor: 25.606

Review 10.  Clinical consequences of clonal hematopoiesis of indeterminate potential.

Authors:  David P Steensma
Journal:  Blood Adv       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.